More recently, we have demonstrated that pentamidine (PTM), an approved antiprotozoal drug known to block S100B activity [11,12], ameliorates clinical disease scores and neuropathologic and biomolecular parameters in the relapsing-remitting experimental autoimmune encephalomyelitis SJL/J mouse model of MS [13]. Here, S100B is linked to myeloid sarcoma.